Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Odevixibat - Albireo Pharma

Next Previous
Drug Profile

Odevixibat - Albireo Pharma

Alternative Names: A-4250; Bylvay; Kayfanda; Kayfanda®; Odevixibat sesquihydrate - Alberio Pharma; ODEVIXIBAT1

Latest Information Update: 12 Sep 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Albireo AB
  • Developer Albireo AB; Albireo Pharma
  • Class Acetamides; Butyric acids; Hepatoprotectants; Small molecules; Sulfones; Thiazepines
  • Mechanism of Action Sodium-bile acid cotransporter inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Intrahepatic cholestasis; Primary biliary cirrhosis; Biliary atresia; Alagille syndrome
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Alagille syndrome; Intrahepatic cholestasis
  • Phase III Biliary atresia
  • Phase II Cholestasis
  • Discontinued Non-alcoholic steatohepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis

Most Recent Events

  • 09 Sep 2025 Preregistration for Alagille syndrome (In adults, In infants, In adolescents, In children) in Canada (PO) prior to September
  • 09 Sep 2025 Registered for Alagille syndrome (In adolescents, In children, In adults, In infants) in Canada (PO)
  • 18 Nov 2024 Efficacy and adverse events data from phase-III Assert-EXT trial in Alagille syndrome released by Ipsen

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top